CSF2 and neoplasm: In the present study GM-CSF was chosen, since it boosted the vaccine efficiency in the first licensed cancer vaccine Provenge [21], and improved patient outcome in phase 3 studies when applied in combination with suitable anti-tumor vaccines [22].